VolitionRx (VNRX) - 13,500-person prospective US trial on deck

07:58 EDT 21 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - VolitionRx: VolitionRx will be participating in a 13,500-patient prospective trial investigating its colorectal Nu.Q™ test (and other biomarkers) in the US. The trial will be run in collaboration with the National Cancer Institute (NCI) and the University of Michigan, which will be bearing the majority of its cost. VolitionRx will only pay $3m over the two to three years the trial is expected to take to complete. We are reducing our valuation to $236m (from $272m) or $8.89 per basic share due to the long timeline in the US.
ISIN: US9286611077

Original Article: VolitionRx (VNRX) - 13,500-person prospective US trial on deck


More From BioPortfolio on "VolitionRx (VNRX) - 13,500-person prospective US trial on deck"

Quick Search


Relevant Topic

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...